https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA approves treosulfan with fludarabine as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS

FDA approves treosulfan with fludarabine as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS

On Jan. 21, 2025, the FDA approved treosulfan (Grafapex, medac GmbH) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome.

administrator

Related Articles